953 Indiana Street
About Alector, LLC
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
20 articles with Alector, LLC
Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported initial positive data from a subset of patients in the company’s INFRONT clinical study of its product candidate, AL001. AL001 is being evaluated for the treatment of patients with frontotemporal dementia with a granulin mutation (FTD-GRN).
A list of the top 10 biotech IPOs from January to the end of June this year shows significant involvement in the Hong Stock exchange, with five companies based in China, and one, Frontage Holdings, operating in both the U.S. and China.
Winterlight is developing speech-based digital biomarkers to monitor disease progression in patients with FTD in collaboration with Alector
Winterlight Labs Inc, a company that develops speech-based digital biomarkers for neuropsychiatric disorders, announced it is developing vocal biomarkers for monitoring disease progression in frontotemporal dementia patients in collaboration with Alector, a biotechnology company developing therapeutics for neurodegeneration.
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INVOKE clinical study of AL002.
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first frontotemporal dementia (FTD) patient in the Phase 1b portion of the INFRONT clinical study of AL001 after successful completion of the healthy volunteer single ascending dose escalation portion of the study.
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
Alector, Inc. announced the pricing of its initial public offering of 9,250,000 shares of common stock to the public at $19.00 per share.
The government shutdown threw a wrench into several biotech company’s plans for initial public offerings (IPOs). Although the government is only guaranteed to stay open until February 15, several biotechs are working to get their IPOs launched in that window. Here’s a look.
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
Alector Strengthens Board of Directors with Appointments of David Wehner, Richard Scheller and Louis Lavigne
Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the following additions to its board as independent directors:
First Clinical Trial of a Program Designed to Address Multiple Brain Pathologies in Alzheimer’s Disease by Reversing Immune Dysfunction
Alector today announced the initiation of its Phase 1 trial called INFRONT, which is evaluating AL001
Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontot...
8/8/2018AL001 is a human recombinant monoclonal antibody, for the treatment of all patients with frontotemporal dementia.
Alector Announces $133 Million in Series E Financing to Advance Broad Portfolio of Immuno-Neurology and Immuno-Oncology Programs
First three programs to focus on Alzheimer’s disease and frontotemporal dementia
South San Francisco-based Alector closed on a Series E financing worth $133 million. The money will be used to advance the company’s clinical programs and expand its discovery platform.
Alector is the latest R&D company to choose to partner with Science Exchange.
AbbVie announced a strategic collaboration with Alector to develop and commercialize drugs for ALZ's disease and other neurodegenerative disorders.